Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

82.62USD
21 Sep 2017
Change (% chg)

$-0.02 (-0.02%)
Prev Close
$82.64
Open
$82.73
Day's High
$83.41
Day's Low
$82.23
Volume
6,194,703
Avg. Vol
9,351,676
52-wk High
$86.27
52-wk Low
$63.76

Select another date:

Thu, Sep 21 2017

BRIEF-Gilead receives approval in Canada for expanded indication of epclusa

* Gilead receives approval in Canada for expanded indication of epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV

BRIEF-Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC Filing‍​

* Gilead Sciences - On September 8, 2017 co entered into a $6.0 billion term loan facility credit agreement - SEC Filing‍​

BRIEF-Gilead Sciences to present at the Morgan Stanley Global Healthcare conference

* Gilead Sciences to present at the Morgan Stanley global healthcare conference on Monday, September 11 Source text for Eikon: Further company coverage:

BRIEF-Gilead Sciences files for potential mixed shelf size not disclosed

* Gilead Sciences Inc files for potential mixed shelf; size not disclosed - SEC filing‍​ Source text: [http://bit.ly/2etaGsh] Further company coverage:

UPDATE 4-Gilead to buy Kite for promising cancer therapies in $12 bln deal

Aug 28 Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

Gilead to buy Kite for promising cancer therapies in $12 billion deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

BRIEF-Gilead says it is not going quiet after Kite deal

* Says it is not going quiet after this deal; will look for more opportunities : conf call

BRIEF-Gilead Sciences to acquire Kite Pharma for $11.9 billion

* Kite Pharma Inc - ‍Gilead will acquire Kite for $180.00 per share in cash​

Gilead to buy Kite Pharma in $11 bln deal - WSJ

Aug 28 Gilead Sciences Inc has agreed to buy Kite Pharma Inc for about $11 billion in an all-cash deal, the Wall Street Journal reported on Monday, citing people familiar with the matter.

BRIEF-Gilead to buy Kite Pharma for roughly $11 billion in cash - WSJ

* Gilead to buy Kite Pharma for roughly $11 billion in cash - WSJ, citing sources Source text - http://on.wsj.com/2giy1NI Further company coverage:

Select another date: